Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2018-03-29
Target enrollment:
Participant gender:
Summary
The goals of the overall study are to evaluate a recommended phase 2 dose and the short and
long term toxicities of the combinations. This is a modified phase I trial of immune
checkpoint inhibitors in combination with mutation - specific targeted therapy (crizotinib or
erlotinib) at conventional doses stratified for presence of ALK (Anaplastic lymphoma kinase)
or EGFR (epidermal growth factor receptor) mutation.
The goals of the overall study are to evaluate a recommended phase 2 dose and the short and
long term toxicities of the combinations.